Invariant NK T cells: Potential for immunotherapeutic targeting with glycolipid antigens

Immunotherapy

Volumn 3, Issue 1, 2011, Pages 59-75

  Van Kaer, Luc ^a   Parekh, Vrajesh V ^a   Wu, Lan ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

galactosylceramide; autoimmunity; cancer; CD1d; glycolipid; immunotherapy; infection; inflammation; innate lymphocyte; invariant NK T cell

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BCG VACCINE; GLYCOSPHINGOLIPID ALPHA GALACTOSYLCERAMIDE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; LENALIDOMIDE; MALARIA VACCINE; T LYMPHOCYTE ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; AUTOIMMUNITY; CHAGAS DISEASE; CLINICAL TRIAL; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; DERMATITIS; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; GRAVES DISEASE; HEPATITIS B; HERPES SIMPLEX; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATION; INFLUENZA; INVARIANT NATURAL KILLER T CELL; JAPANESE ENCEPHALITIS; MALARIA; MALARIA FALCIPARUM; MYASTHENIA GRAVIS; NATURAL KILLER T CELL; NEOPLASM; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; STAPHYLOCOCCUS INFECTION; TUBERCULOSIS; UVEITIS; VACCINATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; IMMUNOTHERAPY; INFECTION; MICE; MICE, INBRED C57BL; NATURAL KILLER T-CELLS; NEOPLASMS; TREATMENT OUTCOME;

EID: 78650575791     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.85     Document Type: Review

References (218)

1. Mueller DL: Mechanisms maintaining peripheral tolerance. Nat. Immunol. 11(1), 21-27 (2010).
2. Jiang H, Chess L: Regulation of immune responses by T cells. N. Engl. J. Med. 354(11), 1166-1176 (2006).
3. Shevach EM: From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 25(2), 195-201 (2006). (Pubitemid 44224153)
4. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H: The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21, 483-513 (2003). (Pubitemid 37174539)
5. Kronenberg M: Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 26, 877-900 (2005). (Pubitemid 40563188)
6. Brigl M, Brenner MB: CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22, 817-890 (2004). (Pubitemid 38680443)
7. Bendelac A, Savage PB, Teyton L: The biology of NKT cells. Annu. Rev. Immunol. 25, 297-336 (2007). (Pubitemid 46697911)
8. Wu L, Gabriel CL, Parekh VV, Van Kaer L: Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Tissue Antigens 73(6), 535-545 (2009).
9. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L: NKT cells: what's in a name? Nat. Rev. Immunol. 4(3), 231-237 (2004). (Pubitemid 38339089)
10. Cohen NR, Garg S, Brenner MB: Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv. Immunol. 102, 1-94 (2009).
11. Gumperz JE, Miyake S, Yamamura T, Brenner MB: Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195(5), 625-636 (2002). (Pubitemid 34461507)
12. + T lymphocytes. J. Immunol. 168(11), 5514-5520 (2002). (Pubitemid 34556130)
13. + NK T cells activated by α-galactosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 168(7), 3140-3144 (2002). (Pubitemid 34250371)
14. Matsuda JL, Naidenko OV, Gapin L et al.: Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192(5), 741-754 (2000).
15. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A: In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191(11), 1895-1903 (2000). (Pubitemid 30390352)
16. Wilson MT, Johansson C, Olivares-Villagomez D et al.: The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl Acad. Sci. USA 100(19), 10913-10918 (2003). (Pubitemid 37140127)
17. Laloux V, Beaudoin L, Jeske D, Carnaud C, Lehuen A: NK T cell-induced protection against diabetes in Vα14-Jα281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J. Immunol. 166(6), 3749-3756 (2001). (Pubitemid 32224898)
18. Swain MG: Natural killer T cells within the liver: conductors of the hepatic immune orchestra. Dig. Dis. 28(1), 7-13 (2010).
19. Laloux V, Beaudoin L, Ronet C, Lehuen A: Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes. J. Immunol. 168(7), 3251-3258 (2002). (Pubitemid 34250385)
20. Hammond KJ, Pellicci DG, Poulton LD et al.: CD1d-restricted NKT cells: an interstrain comparison. J. Immunol. 167(3), 1164-1173 (2001).
21. Rymarchyk SL, Lowenstein H, Mayette J et al.: Widespread natural variation in murine natural killer T-cell number and function. Immunology 125(3), 331-343 (2008).
22. Karadimitris A, Gadola S, Altamirano M et al.: Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc. Natl Acad. Sci. USA 98(6), 2950-2952 (2001). (Pubitemid 32220838)
23. Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D: CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med. 195(7), 869-879 (2002). (Pubitemid 34286758)
24. Exley MA, Koziel MJ: To be or not to be NKT: natural killer T cells in the liver. Hepatology 40(5), 1033-1040 (2004). (Pubitemid 39425556)
25. + cells amass in human omentum and are depleted in patients with cancer and obesity. Eur. J. Immunol. 39(7), 1893-1901 (2009).
26. + Vα24 natural killer T cells in human immunodeficiency virus infection. J. Virol. 76(15), 7528-7534 (2002). (Pubitemid 34760975)
27. Coquet JM, Chakravarti S, Kyparissoudis K et al.: Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc. Natl Acad. Sci. USA 105(32), 11287-11292 (2008).
28. Michel ML, Keller AC, Paget C et al.: Identification of an IL-17-producing NK1.1- iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204(5), 995-1001 (2007). (Pubitemid 46798144)
29. Godfrey DI, Kronenberg M: Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114(10), 1379-1388 (2004). (Pubitemid 40385565)
30. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L: CD1d-restricted iNKT cells, the 'Swiss-army knife' of the immune system. Curr. Opin. Immunol. 20(3), 358-368 (2008).
31. Brutkiewicz RR: CD1d ligands: the good, the bad, and the ugly. J. Immunol. 177, 769-775 (2006).
32. Venkataswamy MM, Porcelli SA: Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin. Immunol. 22, 68-78 (2010).
33. Gapin L: iNKT cell autoreactivity: what is 'self' and how is it recognized? Nat. Rev. Immunol. 10(4), 272-277 (2010).
34. Zhou D, Mattner J, Cantu C et al.: Lysosomal glycosphingolipid recognition by NKT cells. Science 306(5702), 1786-1789 (2004). (Pubitemid 39601398)
35. Van Kaer L, Joyce S: The hunt for iNKT cell antigens: α-galactosidase-deficient mice to the rescue? Immunity 33(2), 143-145 (2010).
36. Chiu YH, Park SH, Benlagha K et al.: Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat. Immunol. 3(1), 55-60 (2002). (Pubitemid 34065618)
37. Speak AO, Salio M, Neville DC et al.: Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl Acad. Sci. USA 104(14), 5971-5976 (2007). (Pubitemid 47175643)
38. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ: Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl Acad. Sci. USA 104(14), 5977-5982 (2007). (Pubitemid 47175644)
39. Christiansen D, Milland J, Mouhtouris E et al.: Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol. 6(7), E172 (2008).
40. Li Y, Thapa P, Hawke D et al.: Immunologic glycosphingolipidomics and NKT cell development in mouse thymus. J. Proteome Res. 8(6), 2740-2751 (2009).
41. Darmoise A, Teneberg S, Bouzonville L et al.: Lysosomal α-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 33(2), 216-228 (2010).
42. Chen X, Wang X, Keaton JM et al.: Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules. J. Immunol. 178(10), 6181-6190 (2007). (Pubitemid 46717400)
43. Fox LM, Cox DG, Lockridge JL et al.: Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol. 7(10), E1000228 (2009).
44. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100(2), 144-148 (2001). (Pubitemid 32703418)
45. Braun NA, Mendez-Fernandez YV, Covarrubias R et al.: Development of spontaneous anergy in invariant natural killer T cells in a mouse model of dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 30(9), 1758-1765 (2010).
46. Mattner J, DeBord KL, Ismail N et al.: Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434(7032), 525-529 (2005). (Pubitemid 40477062)
47. Kinjo Y, Wu DY, Kim G et al.: Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434(7032), 520-525 (2005). (Pubitemid 40477061)
48. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR: Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligand for NKT cells. Eur. J. Immunol. 35(6), 1692-1701 (2005). (Pubitemid 40862317)
49. Kinjo Y, Tupin E, Wu D et al.: Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7(9), 978-986 (2006). (Pubitemid 44263912)
50. Amprey JL, Im JS, Turco SJ et al.: A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J. Exp. Med. 200(7), 895-904 (2004).
51. Fischer K, Scotet E, Niemeyer M et al.: Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc. Natl Acad. Sci. USA 101(29), 10685-10690 (2004). (Pubitemid 38955803)
52. Natori T, Koezuka Y, Higa T: Agelasphins, novel α- galactosylceramides from the marine sponge Agelas mauritianus. Tetrahedron Lett. 34(35), 5591-5592 (1993). nn Demonstration that α-galactosylceramides (α-GalCer) from a marine sponge have potent antimetastatic activities in mice. (Pubitemid 23263311)
53. Kawano T, Cui J, Koezuka Y et al.: CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278(5343), 1626-1629 (1997). nn Identification of α-GalCer as a potent agonist of invariant NK T (iNKT) cells. (Pubitemid 27516282)
54. Brossay L, Chioda M, Burdin N et al.: CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 188(8), 1521-1528 (1998). (Pubitemid 28489589)
55. Thomas TR, Kavlekar DP, LokaBharathi PA: Marine drugs from sponge-microbe association - a review. Mar. Drugs 8(4), 1417-1468 (2010).
56. Borg NA, Wun KS, Kjer-Nielsen L et al.: CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448(7149), 44-49 (2007). (Pubitemid 47037002)
57. Zajonc DM, Kronenberg M: Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells. Immunol. Rev. 230(1), 188-200 (2009).
58. Florence WC, Xia C, Gordy LE et al.: Adaptability of the semi-invariant natural killer T-cell receptor towards structurally diverse CD1d-restricted ligands. EMBO J. 28(22), 3579-3590 (2009).
59. Parekh VV, Lalani S, Van Kaer L: The in vivo response of invariant natural killer T cells to glycolipid antigens. Int. Rev. Immunol. 26(1-2), 31-48 (2007). (Pubitemid 46512168)
60. Matsuda JL, Gapin L, Baron JL et al.: Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl Acad. Sci. USA 100(14), 8395-8400 (2003). (Pubitemid 36842556)
61. Lee PT, Benlagha K, Teyton L, Bendelac A: Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med. 195(5), 637-641 (2002). (Pubitemid 34461508)
62. Crowe NY, Coquet JM, Berzins SP et al.: Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med. 202(9), 1279-1288 (2005).
63. Wingender G, Krebs P, Beutler B, Kronenberg M: Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency. J. Immunol. 185(5), 2721-2719 (2010).
64. Crowe NY, Uldrich AP, Kyparissoudis K et al.: Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol. 171(8), 4020-4027 (2003). (Pubitemid 37238677)
65. Parekh VV, Wilson MT, Olivares-Villagomez D et al.: Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest. 115(9), 2572-2583 (2005). (Pubitemid 41266220)
66. Ulrich AP, Crowe NY, Kyparissoudis K et al.: NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol. 175(5), 3092-3101 (2005). (Pubitemid 41170529)
67. Kim S, Lalani S, Parekh VV, Vincent TL, Wu L, Van Kaer L: Impact of bacteria on the phenotype, functions and therapeutic activities of iNKT cells in mice. J. Clin. Invest. 118(6), 2301-2315 (2008). (Pubitemid 351872347)
68. Chiba A, Dascher CC, Besra GS, Brenner MB: Rapid NKT cell responses are self-terminating during the course of microbial infection. J. Immunol. 181(4), 2292-2302 (2008).
69. Choi HJ, Xu H, Geng Y, Colmone A, Cho H, Wang CR: Bacterial infection alters the kinetics and function of iNKT cell responses. J. Leukoc. Biol. 84, 1462-1471 (2008). (Pubitemid 352774481)
70. Joshi SK, Lang GA, Larabee JL et al.: Bacillus anthracis lethal toxin disrupts TCR signaling in CD1d-restricted NKT cells leading to functional anergy. PLoS Pathog. 5(9), E1000588 (2009).
71. Halder RC, Aguilera C, Maricic I, Kumar V: Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Invest. 117(8), 2302-2312 (2007). (Pubitemid 47219575)
72. Dhodapkar MV, Geller MD, Chang DH et al.: A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197(12), 1667-1676 (2003).
73. Tahir SM, Cheng O, Shaulov A et al.: Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol. 167(7), 4046-4050 (2001). (Pubitemid 32910851)
74. van den Heuvel MJ, Garg N, Van Kaer L, Haeryfar SMM: NKT cell costimulation: experimental progress and therapeutic promise. Trends Mol. Med. DOI:10.1016/j.molmed.2010.10.007 (2010) (Epub ahead of print).
75. Parekh VV, Lalani S, Kim S et al.: PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. J. Immunol. 182(5), 2816-2826 (2009).
76. Chang WS, Kim JY, Kim YJ et al.: Cutting edge: programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J. Immunol. 181(10), 6707-6710 (2008).
77. Carnaud C, Lee D, Donnars O et al.: Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163(9), 4647-4650 (1999). (Pubitemid 29501223)
78. Singh N, Hong S, Scherer DC et al.: Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163(5), 2373-2377 (1999). (Pubitemid 29399153)
79. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM: Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198(2), 267-279 (2003). (Pubitemid 36987852)
80. Wesley JD, Robbins SH, Sidobre S, Kronenberg M, Terrizzi S, Brossay L: Cutting edge: IFN-γ signaling to macrophages is required for optimal Vα14i NK T/NK cell cross-talk. J. Immunol. 174, 3864-3868 (2005). (Pubitemid 40395958)
81. Lang ML: How do natural killer T cells help B cells? Expert Rev. Vaccines 8(8), 1109-1121 (2009).
82. + regulatory T cells in the prevention of autoimmune myasthenia. J. Immunol. 175(12), 7898-7904 (2005). (Pubitemid 41798350)
83. + regulatory T cells. J. Immunol. 177(6), 3695-3704 (2006). (Pubitemid 44359901)
84. Vincent MS, Leslie DS, Gumperz JE, Xiong X, Grant EP, Brenner MB: CD1-dependent dendritic cell instruction. Nat. Immunol. 3(12), 1163-1168 (2002).
85. Cui J, Shin T, Kawano T et al.: Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278(5343), 1623-1626 (1997). (Pubitemid 27516281)
86. Burdin N, Brossay L, Kronenberg M: Immunization with α- galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol. 29(6), 2014-2025 (1999). (Pubitemid 29265558)
87. Hong S, Wilson MT, Serizawa I et al.: The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7(9), 1052-1056 (2001). nn First demonstration of the therapeutic activities of α-GalCer in autoimmunity. (Pubitemid 32937387)
88. Kim JO, Kim DH, Chang WS et al.: Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model. J. Allergy Clin. Immunol. 114(6), 1332-1338 (2004).
89. Galli G, Nuti S, Tavarini S et al.: CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med. 197(8), 1051-1057 (2003). (Pubitemid 36523203)
90. Devera TS, Shah HB, Lang GA, Lang ML: Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur. J. Immunol. 38(4), 1001-1011 (2008).
91. Galli G, Pittoni P, Tonti E et al.: Invariant NKT cells sustain specific B cell responses and memory. Proc. Natl Acad. Sci. USA 104(10), 3984-3989 (2007). (Pubitemid 47181565)
92. Lang GA, Exley MA, Lang ML: The CD1d-binding glycolipid α-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology 119(1), 116-125 (2006).
93. Lang GA, Devera TS, Lang ML: Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. Blood 111(4), 2158-2162 (2008).
94. Lindqvist M, Persson J, Thorn K, Harandi AM: The mucosal adjuvant effect of α-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J. Immunol. 182(10), 6435-6443 (2009).
95. Devera TS, Aye LM, Lang GA, Joshi SK, Ballard JD, Lang ML: CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies. Infect. Immun. 78(4), 1610-1617 (2010).
96. Miyamoto K, Miyake S, Yamamura T: A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 413(6855), 531-534 (2001). n Demonstration that the α-GalCer analog OCH induces a Th2-biased cytokine response in mice that can ameliorate experimental autoimmune encephalomyelitis. (Pubitemid 32938752)
97. Yu KO, Im JS, Molano A et al.: Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl Acad. Sci. USA 102(9), 3383-3388 (2005). (Pubitemid 40328054)
98. Schmieg J, Yang G, Franck RW, Tsuji M: Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med. 198(11), 1631-1641 (2003). n Demonstration that the α-GalCer analog α-C-GalCer induces a Th1-biased cytokine response with superior activities against malaria and tumor metastases in mice. (Pubitemid 37494156)
99. Tashiro T, Sekine-Kondo E, Shigeura T et al.: Induction of Th1-biased cytokine production by a-carba-GalCer, a neoglycolipid ligand for NKT cells. Int. Immunol. 22(4), 319-328 (2010).
100. Li X, Fujio M, Imamura M et al.: Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl Acad. Sci. USA 107(29), 13010-13015 (2010).
101. Lin KH, Liang JJ, Huang WI et al.: In vivo protection of bacterial and viral infections in murine models using a synthetic new α-GalCer analog. Antimicrob. Agents Chemother. 54(10), 4129-4136 (2010).
102. Sullivan BA, Nagarajan NA, Wingender G et al.: Mechanisms for glycolipid antigen-driven cytokine polarization by Vα14i NKT cells. J. Immunol. 184(1), 141-153 (2010). n Demonstration that the pharmacokinetic properties of iNKT cell antigens determine the cytokine profile induced.
103. Oki S, Chiba A, Yamamura T, Miyake S: The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113(11), 1631-1640 (2004). (Pubitemid 39071687)
104. Bezbradica JS, Stanic AK, Matsuki N et al.: Distinct roles of dendritic cells and B cells in Vα14Ja18 natural T cell activation in vivo. J. Immunol. 174(8), 4694-4705 (2005). (Pubitemid 40504552)
105. Bai L, Sagiv Y, Liu Y et al.: Lysosomal recycling terminates CD1d-mediated presentation of short and polyunsaturated variants of the NKT cell lipid antigen aGalCer. Proc. Natl Acad. Sci. USA 106(25), 10254-10259 (2009).
106. Im JS, Arora P, Bricard G et al.: Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30(6), 888-898 (2009).
107. Nieuwenhuis EE, Matsumoto T, Exley M et al.: CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat. Med. 8(6), 588-593 (2002). (Pubitemid 34633436)
108. Minagawa S, Ohyama C, Hatakeyama S, Tsuchiya N, Kato T, Habuchi T: Activation of natural killer T cells by α-galactosylceramide mediates clearance of bacteria in murine urinary tract infection. J. Urol. 173(6), 2171-2174 (2005). (Pubitemid 40675275)
109. + natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect. 9(3), 364-374 (2007). (Pubitemid 46350859)
110. Chackerian A, Alt J, Perera V, Behar SM: Activation of NKT cells protects mice from tuberculosis. Infect. Immun. 70, 6302-6309 (2002). (Pubitemid 35192722)
111. Sada-Ovalle I, Skold M, Tian T, Besra GS, Behar SM: α- galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am. J. Respir. Crit. Care Med. 82(6), 841-847 (2010).
112. + cells into the liver. Eur. J. Immunol. 40(5), 1328-1341 (2010).
113. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M et al.: α-galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc. Natl Acad. Sci. USA 97(15), 8461-8466 (2000). n First demonstration of the therapeutic activities of iNKT cell activation against infection. (Pubitemid 30639695)
114. Duthie MS, Kahn SJ: Treatment with α-galactosylceramide before Trypanosoma cruzi infection provides protection or induces failure to thrive. J. Immunol. 168(11), 5778-5785 (2002).
115. + natural killer T cells by α-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69(1), 213-220 (2001). (Pubitemid 32038317)
116. Ho LP, Denney L, Luhn K, Teoh D, Clelland C, McMichael AJ: Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection. Eur. J. Immunol. 38(7), 1913-1922 (2008).
117. + T cells and amplification of antiviral immune responses to respiratory syncytial virus. J. Virol. 76(9), 4294-4303 (2002). (Pubitemid 34309565)
118. Van Dommelen SL, Tabarias HA, Smyth MJ, Degli-Eposti MA: Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J. Virol. 77, 1877-1884 (2003).
119. Exley MA, Bigley NJ, Cheng O et al.: CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus. J. Leukoc. Biol. 69(5), 713-718 (2001). (Pubitemid 32466408)
120. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192(7), 921-930 (2000).
121. Stanley AC, Zhou Y, Amante FH et al.: Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog. 4(2), E1000028 (2008). (Pubitemid 351340698)
122. Bharhani MS, Chiu B, Na KS, Inman RD: Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis. Int. Immunol. 21(7), 859-870 (2009).
123. Bilenki L, Wang S, Yang J, Fan Y, Joyee AG, Yang X: NK T cell activation promotes Chlamydia trachomatis infection in vivo. J. Immunol. 175(5), 3197-3206 (2005). (Pubitemid 41170540)
124. Woltman AM, Ter Borg MJ, Binda RS et al.: α-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial. Antivir. Ther. 14(6), 809-818 (2009).
125. Veldt BJ, van der Vliet HJ, von Blomberg BM et al.: Randomized placebo controlled Phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C. J. Hepatol. 47(3), 356-365 (2007).
126. Kim S, Lalani S, Parekh VV, Wu L, Van Kaer L: Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev. Vaccines 7(10), 1519-1532 (2008). (Pubitemid 351636003)
127. Cerundolo V, Silk JD, Masri SH, Salio M: Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol. 9(1), 28-38 (2009).
128. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al.: Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195(5), 617-624 (2002). n First evidence for the efficacy of α-GalCer as a vaccine adjuvant. (Pubitemid 34461506)
129. Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY: α- galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175(5), 3309-3317 (2005).
130. Youn HJ, Ko SY, Lee KA et al.: A single intranasal immunization with inactivated influenza virus and α-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 25(28), 5189-5198 (2007).
131. Guillonneau C, Mintern JD, Hubert FX et al.: Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc. Natl Acad. Sci. USA 106(9), 3330-3335 (2009).
132. Kopecky-Bromberg SA, Fraser KA, Pica N et al.: α-C- galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27(28), 3766-3774 (2009).
133. Huang Y, Chen A, Li X et al.: Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine 26(15), 1807-1816 (2008).
134. Noda K, Kodama S, Umemoto S, Abe N, Hirano T, Suzuki M: Nasal vaccination with P6 outer membrane protein and α-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx. Vaccine 28(31), 5068-5074 (2010).
135. Venkataswamy MM, Baena A, Goldberg MF et al.: Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 183(3), 1644-1656 (2009).
136. Hayakawa Y, Rovero S, Forni G, Smyth MJ: α-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc. Natl Acad. Sci. USA 100(16), 9464-9469 (2003). (Pubitemid 37033951)
137. Kawano T, Cui J, Koezuka Y et al.: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl Acad. Sci. USA 95(10), 5690-5693 (1998). (Pubitemid 28224157)
138. Smyth MJ, Crowe NY, Pellicci DG et al.: Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99(4), 1259-1266 (2002).
139. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM: The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199(12), 1607-1618 (2004). (Pubitemid 38821994)
140. Nakagawa R, Inui T, Nagafune I et al.: Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by α-galactosylceramide. J. Immunol. 172(11), 6550-6557 (2004). (Pubitemid 38669089)
141. Hayakawa Y, Takeda K, Yagita H et al.: IFN-γamma;-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 100(5), 1728-1733 (2002). (Pubitemid 34925151)
142. Fujii S, Shimizu K, Hemmi H et al.: Glycolipid α-C- galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl Acad. Sci. USA 103, 11252-11257 (2006). (Pubitemid 44156505)
143. Fujii S, Shimizu K, Kronenberg M, Steinman RM: Prolonged IFN-γamma;-producing NKT response induced with α-galactosylceramide- loaded DCs. Nat. Immunol. 3(9), 867-874 (2002).
144. Stirnemann K, Romero JF, Baldi L et al.: Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice. J. Clin. Invest. 118(3), 994-1005 (2008). (Pubitemid 351364607)
145. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y: Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201(12), 1973-1985 (2005). (Pubitemid 41002933)
146. Silk JD, Hermans IF, Gileadi U et al.: Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest. 114(12), 1800-1811 (2004). (Pubitemid 40385536)
147. Liu K, Idoyaga J, Charalambous A et al.: Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J. Exp. Med. 202(11), 1507-1516 (2005). (Pubitemid 41746597)
148. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S: Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med. 204(11), 2641-2653 (2007). (Pubitemid 350063944)
149. Giaccone G, Punt CJA, Ando Y et al.: A Phase I study of natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8(12), 3702-3709 (2002). (Pubitemid 35424759)
150. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103(2), 383-389 (2004). (Pubitemid 38140063)
151. Ishikawa A, Motohashi S, Ishikawa E et al.: A Phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11(5), 1910-1917 (2005). (Pubitemid 40471857)
152. Chang DH, Osman K, Connolly J et al.: Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosylceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201(9), 1503-1517 (2005). (Pubitemid 40664093)
153. Uchida T, Horiguchi S, Tanaka Y et al.: Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57(3), 337-345 (2008). (Pubitemid 350295376)
154. Motohashi S, Ishikawa A, Ishikawa E et al.: A Phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 12(20 Pt 1), 6079-6086 (2006). nn First evidence for therapeutic efficacy of activated iNKT cells in human cancer patients. (Pubitemid 44703772)
155. Motohashi S, Nagato K, Kunii N et al.: A Phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol. 182(4), 2492-2501 (2009). nn First evidence for therapeutic efficacy of activated iNKT cells in human cancer patients.
156. Kunii N, Horiguchi S, Motohashi S et al.: Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 100(6), 1092-1098 (2009).
157. Motohashi S, Nakayama T: Natural killer T cell-mediated immunotherapy for malignant diseases. Front. Biosci. S1, 108-116 (2009).
158. Fujii S, Motohashi S, Shimizu K, Nakayama T, Yoshiga Y, Taniguchi M: Adjuvant activity mediated by iNKT cells. Semin. Immunol. 22(2), 97-102 (2010).
159. Chang DH, Liu N, Klimek V et al.: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108(2), 618-621 (2006). (Pubitemid 44061362)
160. Sharif S, Arreaza GA, Zucker P et al.: Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7(9), 1057-1062 (2001). nn First demonstration of the therapeutic activities of α-GalCer in autoimmunity. (Pubitemid 32937388)
161. Naumov YN, Bahjat KS, Gausling R et al.: Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl Acad. Sci. USA 98(24), 13838-13843 (2001). nn First demonstration of the therapeutic activities of α-GalCer in autoimmunity. (Pubitemid 33115985)
162. Wang B, Geng YB, Wang CR: CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194(3), 313-320 (2001). nn First demonstration of the therapeutic activities of α-GalCer in autoimmunity. (Pubitemid 32730805)
163. Wu L, Van Kaer L: NKT cells and diabetes. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G919-G922 (2007).
164. Driver JP, Scheuplein F, Chen YG, Grier AE, Wilson SB, Serreze DV: Invariant natural killer T-cell control of Type 1 diabetes: a dendritic cell genetic decision of a silver bullet or Russian roulette. Diabetes 59(2), 423-432 (2010).
165. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A: NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic β cells. Immunity 17(6), 725-736 (2002). (Pubitemid 35477792)
166. Chen YG, Choisy-Rossi CM, Holl TM et al.: Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. J. Immunol. 174(3), 1196-1204 (2005).
167. Wang J, Cho S, Ueno A et al.: Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation. J. Immunol. 181(4), 2438-2445 (2008).
168. Mi Q-S, Ly D, Zucker P, McGarry M, Delovitch TL: Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T cells. Diabetes 53(5), 1303-1310 (2004). (Pubitemid 38569017)
169. Mizuno M, Masumura M, Tomi C et al.: Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice. J. Autoimmun. 23(4), 293-300 (2004). (Pubitemid 39574804)
170. Forestier C, Takaki SA, Molano A et al.: Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J. Immunol. 178, 1415-1425 (2007). (Pubitemid 46154612)
171. Ly D, Tohn R, Rubin B et al.: An α-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent Type 1 diabetes. Clin. Exp. Immunol. 160(2), 185-198 (2010).
172. Van Kaer L: α-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5(1), 31-42 (2005). (Pubitemid 40070329)
173. Singh AK, Wilson MT, Hong S et al.: Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1801-1811 (2001). (Pubitemid 34028659)
174. Jahng AW, Maricic I, Pedersen B et al.: Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194(12), 1789-1799 (2001). (Pubitemid 34028658)
175. Mars LT, Araujo L, Kerschen P et al.: Invariant NKT cells inhibit development of the Th17 lineage. Proc. Natl Acad. Sci. USA 106(15), 6238-6243 (2009).
176. Furlan R, Bergami A, Cantarella D et al.: Activation of invariant NKT cells by α-GalCer administration protects mice from MOG35-55 induced EAE: critical roles for administration route and IFN-γ. Eur. J. Immunol. 33(7), 1830-1838 (2003). (Pubitemid 37120854)
177. Kojo S, Seino K-I, Harada M et al.: Induction of regulatory properties in dendritic cells by Vα14 NKT cells. J. Immunol. 175(6), 3648-3655 (2005). (Pubitemid 41292024)
178. Pal E, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T: Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14 NK T cells. J. Immunol. 166(1), 662-668 (2001). (Pubitemid 32038491)
179. Morshed SR, Takahashi T, Savage PB, Kambham N, Strober S: β-galactosylceramide alters invariant natural killer T cell function and is effective treatment for lupus. Clin. Immunol. 132(3), 321-333 (2009).
180. Parekh VV, Singh AK, Wilson MT et al.: Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol. 173(6), 3693-3706 (2004).
181. Coppieters K, Dewint P, Van Beneden K et al.: NKT cells: manipulable managers of joint inflammation. Rheumatology 46(4), 565-571 (2007). (Pubitemid 46523297)
182. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S: Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of α-galactosylceramide. Arthritis Rheum. 50(1), 305-313 (2004). (Pubitemid 38084316)
183. Coppieters K, Van Beneden K, Jacques P et al.: A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. J. Immunol. 179(4), 2300-2309 (2007).
184. Kim HY, Kim HJ, Min HS et al.: NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor b1 production. J. Exp. Med. 201(1), 41-47 (2005).
185. Takagi D, Iwabuchi K, Maeda M et al.: Natural killer T cells ameliorate antibody-induced arthritis in macrophage migration inhibitory factor transgenic mice. Int. J. Mol. Med. 18(5), 829-836 (2006).
186. Grajewski RS, Hansen AM, Agarwal RK et al.: Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-γ production and dampening of the adaptive Th1 and Th17 responses. J. Immunol. 181(7), 4791-4797 (2008).
187. Major AS, Singh RR, Joyce S, Van Kaer L: The role of invariant natural killer T cells in lupus and atherogenesis. Immunol. Res. 34(1), 49-66 (2006). (Pubitemid 43780376)
188. Yang J-Q, Saxena V, Xu H, Van Kaer L, Wang CR, Singh RR: Repeated α-galactosylceramide administration results in expansion of Vα14 NKT cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J. Immunol. 171(8), 4439-4446 (2003). (Pubitemid 37238724)
189. Zeng D, Liu Y, Sidobre S, Kronenberg M, Strober S: Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J. Clin. Invest. 112(8), 1211-1222 (2003). (Pubitemid 38056298)
190. Singh AK, Yang J-Q, Parekh VV et al.: The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur. J. Immunol. 35(4), 1143-1154 (2005).
191. Vas J, Mattner J, Richardson S et al.: Regulatory roles for NKT cell ligands in environmentally induced autoimmunity. J. Immunol. 181(10), 6779-6788 (2008).
192. Nagayama Y, Watanabe K, Niwa M, McLachlan SM, Rapoport B: Schistosoma mansoni and α-galactosylceramide: prophylactic effect of Th1 immune suppression in a mouse model of Graves' hyperthyroidism. J. Immunol. 173(3), 2167-2173 (2004). (Pubitemid 38971656)
193. Ueno Y, Tanaka S, Sumii M et al.: Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice. Infl. Bow. Dis. 11(1), 35-41 (2005). (Pubitemid 40340254)
194. Saubermann LJ, Beck P, De Jong YP et al.: Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 119(1), 119-128 (2000). (Pubitemid 30452585)
195. Numata Y, Tazuma S, Ueno Y, Nishioka T, Hyogo H, Chayama K: Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig. Dis. Sci. 50(10), 1844-1851 (2005). (Pubitemid 41413901)
196. Naidenko OV, Maher JK, Ernst WA, Sakai T, Modlin RL, Kronenberg M: Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J. Exp. Med. 190(8), 1069-1080 (1999). (Pubitemid 29496500)
197. Nieuwenhuis EES, Gillessen S, Scheper RJ et al.: CD1d and CD1d-restricted iNKT-cells play a pivotal role in contact hypersensitivity. Exp. Derm. 14, 250-258 (2005). (Pubitemid 40485452)
198. + T cells. Proc. Natl Acad. Sci. USA 103(8), 2782-2787 (2006). (Pubitemid 43306626)
199. Matsuda H, Suda T, Sato J et al.: α-galactosylceramide, a ligand of natural killer T cells, inhibits allergic airway inflammation. Am. J. Respir. Cell. Mol. Biol. 33, 22-31 (2005). (Pubitemid 40961010)
200. Hachem P, Lisbonne M, Michel ML et al.: α-galactosylceramide- induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-γ. Eur. J. Immunol. 35(10), 2793-2802 (2005). (Pubitemid 41555076)
201. Morishima Y, Ishii Y, Kimura T et al.: Suppression of eosinophilic airway inflammation by treatment with α-galactosylceramide. Eur. J. Immunol. 35(10), 2803-2814 (2005). (Pubitemid 41555077)
202. Lombardi V, Stock P, Singh AK et al.: A CD1d-dependent antagonist inhibits the activation of invariant NKT cells and prevents development of allergen-induced airway hyperreactivity. J. Immunol. 184(4), 2107-2115 (2010).
203. Matsuda H, Takeda K, Koya T et al.: Plasticity of invariant NKT cell regulation of allergic airway disease is dependent on IFN-γ production. J. Immunol. 185(1), 253-262 (2010).
204. Fukushima A, Sumi T, Fukuda K et al.: Modulation of murine experimental allergic conjunctivitis by treatment with α-galactosylceramide. Immunol. Lett. 107(1), 32-40 (2006). (Pubitemid 44332545)
205. Tupin E, Nicoletti A, Elhage R et al.: CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199(3), 417-422 (2004). (Pubitemid 38252053)
206. Major AS, Wilson MT, McCaleb JL et al.: Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 24(12), 2351-2357 (2004).
207. Nakai Y, Iwabuchi K, Fujii S et al.: Natural killer T cells accelerate atherogenesis in mice. Blood 104(7), 2051-2059 (2004). (Pubitemid 39297856)
208. van Puijvelde GH, van Wanrooij EJ, Hauer AD, de Vos P, van Berkel TJ, Kuiper J: Effect of natural killer T cell activation on the initiation of atherosclerosis. Thromb. Haemost. 102(2), 223-230 (2009).
209. Oh K, Kim S, Park SH et al.: Direct regulatory role of NKT cells in allogeneic graft survival is dependent on the quantitative strength of antigenicity. J. Immunol. 174(4), 2030-2036 (2005). (Pubitemid 40223945)
210. Mattarollo SR, Yong M, Tan L, Frazer IH, Leggatt GR: Secretion of IFN-γ but not IL-17 by CD1d-restricted NKT cells enhances rejection of skin grafts expressing epithelial cell-derived antigen. J. Immunol. 184(10), 5663-5669 (2010).
211. + cells mediates early graft loss of syngeneic transplanted islets. J. Exp. Med. 202(7), 913-918 (2005). (Pubitemid 41398198)
212. Haraguchi K, Takahashi T, Matsumoto A et al.: Host-residual invariant NK T cells attenuate graft-versus-host immunity. J. Immunol. 175(2), 1320-1328 (2005). (Pubitemid 41095022)
213. Hashimoto D, Asakura S, Miyake S et al.: Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 174(1), 551-556 (2005). (Pubitemid 40007446)
214. Kuns RD, Morris ES, Macdonald KP et al.: Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after α-galactosylceramide administration. Blood 113(23), 5999-6010 (2009).
215. Osman Y, Kawamura T, Naito T et al.: Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30(7), 1919-1928 (2000). (Pubitemid 30456188)
216. Ito K, Karasawa M, Kawano T et al.: Involvement of decidual Vα14 NKT cells in abortion. Proc. Natl Acad. Sci. USA 97(2), 740-744 (2000). (Pubitemid 30070379)
217. Motohashi S, Nakayama T: Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci. 99(4), 638-645 (2008). (Pubitemid 351448064)
218. Porcelli SA, Modlin RL: The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17, 297-329 (1999).